Internal Medicine, Rheumatology · La Mesa, CA
NPI
1417117839
Since 2008
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
8860 Center Dr Ste 400
La Mesa, CA, 91942
Phone (619) 229-1995
Groups this clinician bills Medicare through
Medicare paid, 2024
$75K
2,656 services
Medicare patients, 2024
311
Average age 70
Drug cost, 2024
$9.4M
3,085 prescriptions
Company payments, 2025
$47K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Roshan Kotha was code J1010 (injection, methylprednisolone acetate, 1 mg), 1,716 times for 35 patients. In total Roshan Kotha billed 2,656 services in 12 codes, and Medicare paid $75K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-09-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,716 | 35 | $0.09 | $162 |
| 99214 Office E&M - Established | Office | 510 | 250 | $88.58 | $45K |
| 99215 Office E&M - Established | Office | 110 | 68 | $119.82 | $13K |
| 99204 Office E&M - New | Office | 90 | 90 | $113.22 | $10K |
| 96372 Injection Administration | Office | 82 | 38 | $10.31 | $845 |
| 77080 Standard X-ray | Office | 56 | 56 | $41.32 | $2,314 |
| 99213 Office E&M - Established | Office | 42 | 36 | $66.36 | $2,787 |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 35 | 16 | $3.35 | $117 |
By year: 2022 $81K for 1,098 services; 2023 $81K for 990 services; 2024 $75K for 2,656 services.
Medicare prescription drug claims, 2024
In 2024, the drug Roshan Kotha prescribed most often to Medicare patients was Humira(Cf) Pen (Adalimumab), with 346 prescriptions and refills. In total Roshan Kotha wrote 3,085 Medicare prescriptions that cost $9.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | 346 | 346 | 54 | $2.5M |
| Prolia Denosumab | 225 | 1,350 | 144 | $376K |
| Methotrexate Methotrexate Sodium | 222 | 402 | 73 | $7,476 |
| Enbrel Sureclick Etanercept | 211 | 212 | 32 | $1.5M |
| Prednisone Generic | 206 | 262 | 56 | $947 |
| Hydroxychloroquine Sulfate Generic | 175 | 376 | 76 | $9,615 |
| Rinvoq Upadacitinib | 135 | 135 | 16 | $830K |
| Alendronate Sodium Generic | 129 | 290 | 46 | $975 |
| Evenity (2 Syringes) Romosozumab-Aqqg | 126 | 126 | 24 | $300K |
| Orencia Clickject Abatacept | 111 | 111 | 21 | $630K |
| Sulfasalazine Generic | 93 | 130 | 31 | $1,707 |
| Xeljanz Xr Tofacitinib Citrate | 87 | 87 | Under 11 | $487K |
| Gabapentin Generic | 75 | 123 | 30 | $654 |
| Benlysta Belimumab | 60 | 63 | Under 11 | $285K |
| Tymlos Abaloparatide | 45 | 46 | Under 11 | $121K |
Brand drugs: 1,758 claims; generic drugs: - claims; opioid claims: 34.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Roshan Kotha $47K ($47K in general payments such as food, travel and fees) from 23 companies. The largest payer was Janssen Biotech, Inc. with $20K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 59 | $20K |
| Abbvie Inc. ABBV | 64 | $18K |
| E.R. Squibb & Sons, L.L.C. BMY | 16 | $5,058 |
| Amgen Inc. AMGN | 51 | $1,004 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $338 |
| UCB, Inc. UCB.BR | 23 | $315 |
| ANI Pharmaceuticals, Inc. ANIP | 12 | $282 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $266 |
| Mallinckrodt Hospital Products Inc. | 10 | $242 |
| GlaxoSmithKline, LLC. GSK | 11 | $219 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.